Media

Join us at AACR's Annual Meeting which is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share

Join us at the mRNA Process Development & Manufacturing Summit 2023 at the Boston Convention and Exhibit Center in Boston, MA, September 27-28. ITI Director of RNA Therapeutics Development, Prakash

Immunomic Therapeutics' article titled, "LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition," has been published in Frontiers

Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme -Top-Line Data Expected in the Second Quarter of

Immunomic Therapeutics' Prakash Koodathingal, Director of RNA Therapeutics Development, shares his insight into CQAs for saRNA for GEN magazine's "Expansion of the RNA Technology Universe." Read the full article here:

July 14, 2023 Immunomic Therapeutics is highlighted in Washington Business Journal's cover story, “Life sciences funding is tough, but there are still avenues to money.” WBJ talks about how a

In the Washington Post article "How Jimmy Carter boosted a life-saving cancer drug," our scientific advisor Dr. Drew Pardoll provides his outlook on Carter's impact on immune therapy. Pardoll, the

March 06, 2023 09:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that

The article "Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic," authored by our academic collaborator, Dr. Duane Mitchell was released in AACR's journal of Clinical Cancer Research on March

Save the Date!

38th Annual Meeting & Pre-Conference Programs (SITC 2023) Explore comprehensive resources and educational opportunities for cancer patients and those who advocate for them. Track the latest advancements and educational opportunities in

This meeting will feature in-person presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy,